Modified antibodies, or antigen-binding fragments thereof, to theextracellular domain of human prostate specific membrane antigen (PSMA) areprovided. The modified anti-PSMA antibodies, or antigen-binding fragmentsthereof, have been rendered less immunogenic compared to their unmodifiedcounterparts to a given species, e.g., a human. Pharmaceutical compositionsincluding the aforesaid antibodies, nucleic acids, recombinant expressionvectors and host cells for making such antibodies and fragments are alsodisclosed. Methods of using the antibodies of the invention to detect humanPSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressingcancer or prostatic cell, either in vitro or in vivo, are also provided.
